Session Detail


Session Title: Novel Therapeutics
Session Type: Clinical Trials Symposium
Session Start/End Time: Tuesday, Apr 08, 2014, 10:30 AM -12:30 PM
Location: Room 25, San Diego Convention Center
CME: CME-Designated
CME/CE Hours: 2
Presentations:
Chairperson
Tuesday, Apr 08, 2014, 10:30 AM -12:30 PM
Jordi Rodon. Vall d'Hebron Univ. Hospital, Barcelona, Spain
CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
Tuesday, Apr 08, 2014, 10:30 AM -10:50 AM
Rodrigo Dienstmann1, Rastilav Bahleda2, Barbara Adamo3, Jordi Rodon3, Andrea Varga2, Anas Gazzah2, Suso Platero4, Hans Smit5, Timothy Perera5, Bob Zhong4, Kim Stuyckens5, Yusri Elsayed4, Chris Takimoto4, Vijay Peddareddigari4, Josep Tabernero3, Feng Roger Luo4, Jean-Charles Soria2. 1Fred Hutchinson Cancer Research Center, Seattle, WA; 2Gustave Roussy Institute, Villejuif, France; 3Vall D'Hebron Hospital, Barcelona, Spain; 4Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ; 5Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
Tuesday, Apr 08, 2014, 10:50 AM -11:10 AM
Lecia V. Sequist1, Phillippe Cassier2, Andrea Varga3, Josep Tabernero4, Jan HM Schellens5, Jean-Pierre Delord6, Patricia LoRusso7, D. Ross Camidge8, Manuel Hidalgo Medina9, Martin Schuler10, Mario Campone11, G. Gary Tian12, Steven Wong13, Jesus Corral14, Randi Isaacs15, Suman K. Sen16, Diana Graus Porta17, Swarupa G. Kulkarni16, Caroline Lefebvre18, Jürgen Wolf19. 1Massachusetts General Hospital, Boston, MA; 2Centre Léon Bérard, Lyon, France; 3Institut Gustave Roussy, France; 4Vall d'Hebron University Hospital, Barcelona, Spain; 5The Netherlands Cancer Institute, Amsterdam, Netherlands; 6Institut Claudius Regaud, Toulouse, France; 7Karmanos Cancer Institute, Detroit, MI; 8University of Colorado, Aurora, CO; 9Spanish National Cancer Research Centre (CNIO), Madrid, Spain; 10West German Cancer Center, University Duisburg-Essen, Essen, Germany; 11Centre René Gauducheau, Nantes, France; 12The West Clinic, Memphis, TN; 13UCLA Medical Center, Los Angeles, CA; 14University Hospital Virgen del Rocío, Seville, Spain; 15Novartis OTM, East Hanover, NJ; 16Novartis Pharmaceuticals Corporation, East Hanover, NJ; 17NIBR Oncology, Klybeckstrasse, Switzerland; 18Novartis OTM, Basel, Switzerland; 19University Hospital of Cologne, Köln, Germany
Discussant
Tuesday, Apr 08, 2014, 11:10 AM -11:30 AM
Paul K. Paik. Mem. Sloan-Kettering Cancer Ctr., New York, NY
CT327: Multicenter phase I study of MRX34, a first-in-class microRNA miR-34 mimic liposomal injection
Tuesday, Apr 08, 2014, 11:30 AM -11:50 AM
Muhammad Shaalan Beg, Mitesh Borad, Jasgit Sachdev, David S. Hong, Susan Smith, Andres Bader, Jay Stoudemire, Sinil Kim, Andrew Brenner. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, Mayo Clinic, Scottsdale, AZ, Virginia G Piper Cancer Center, Scottsdale, AZ, The University of Texas MD Anderson Cancer Center, Houston, TX, MIRNA Therapeutics Inc., Austin, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX
Discussant
Tuesday, Apr 08, 2014, 11:50 AM -12:00 PM
Carlo M. Croce. The Ohio State Univ. Comp. Cancer Ctr., Columbus, OH
CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors
Tuesday, Apr 08, 2014, 12:00 PM -12:20 PM
Johanna C. Bendell, Patricia LoRusso, Daniel C. Cho, Luna Musib, Yibing Yan, Ilsung Chang, Premal Patel, Iris T. Chang, Raymond D. Meng, Geoffrey I. Shapiro. Sarah Cannon Research Institute, Nashville, TN, Barbara Ann Karmanos Cancer Institute, Detroit, MI, Beth Israel Deaconess Medical Center, Boston, MA, Genentech, Inc., South San Francisco, CA, Dana Farber Cancer Institute, Boston, MA
Discussant
Tuesday, Apr 08, 2014, 12:20 PM -12:30 PM
Anthony W. Tolcher. START, San Antonio, TX